Protalix BioTherapeutics (PLX) Hit as EMA CHMP Denies MAA for Taliglucerase Alfa
Tweet Send to a Friend
Up)
Protalix BioTherapeutics (AMEX: PLX) shares are lower following news taliglucerase alfa did not get marketing approval from the EMA CHMP.
Shares are down about 14 percent ahead of the bell Friday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares are down about 14 percent ahead of the bell Friday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Fannie Mae, Freddie Mac Surge as Seriously Delinquent Rate Falls Below 3%
- UPDATE: Crash in American Electric Power (AEP) & NextEra Energy (NEE) Adds to Jitters
- UPDATE: Intuitive Surgical (ISRG) Jury Reaches Positive Verdict in Robot Case; Shares Rise
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
